Untangling chromosomal and hormonal effects to make sex-specific endothelial OCT4 clinically actionable

The vascular biology community has just been handed both a discovery and a warning in a single package. In a Letter published on 12 February 2026 in the journal Angiogenesis, M. Vijayasimha of Chandigarh University, M. Srikanth of the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in Rohtak, and Rajeev Kumar Jha of The Neotia University in Kolkata argue that a recently reported role for the pluripotency factor OCT4 in driving sex-specific angiogenic responses could reshape how new blood vessels are studied and targeted, but only if the field first repairs two deep methodological flaws. The first is the chronic entanglement of sex chromosomes with sex hormones in experimental design. The second is the absence of standardized translational endpoints for measuring angiogenesis across laboratories. Until those problems are fixed, the authors contend, findings such as the OCT4 effect risk remaining biologically intriguing yet clinically unusable, unable to inform sex-aware treatment of ischemic disease, wound repair, retinal degeneration, or cancer. The Letter is not a rebuttal of the underlying science but a demand for the infrastructure that would let it survive translation.

The commentary responds directly to a study by Shin and colleagues, published in Angiogenesis, which reported sex-specific angiogenic responses in endothelial cells attributable to the pluripotency factor OCT4. Endothelial cells form the inner lining of every artery, vein, and capillary, and they orchestrate angiogenesis — the construction of new vessels from an existing network — by proliferating, migrating through tissue, remodeling extracellular matrix with proteases, and organizing themselves into patent, perfusable tubes in response to cues such as vascular endothelial growth factor, or VEGF. According to the underlying study, male and female endothelial cells do not run this program identically, and OCT4 appears to be one of the molecular determinants of that divergence. The letter’s authors treat the result as a genuine advance, because it points to a transcriptional regulator, rather than a circulating hormone alone, as a driver of vascular sex differences. But they frame the discovery as standing at a decision point: either the field builds the experimental architecture needed to interpret it rigorously, or it becomes another compelling result whose translational meaning dissolves under methodological scrutiny.

OCT4, encoded by the POU5F1 gene, is one of the most storied molecules in developmental biology. As an octamer-binding transcription factor, it binds specific DNA motifs and controls the gene networks that keep embryonic stem cells in an undifferentiated, self-renewing state; it is also one of the four Yamanaka factors used to reprogram adult cells into induced pluripotent stem cells, work recognized with the 2012 Nobel Prize in Physiology or Medicine. In most adult tissues, canonical OCT4 expression is silenced. Yet accumulating evidence indicates that the factor can persist or be reactivated in selected adult cell types, including endothelial cells engaged in angiogenic behavior, where it appears to push cells toward the proliferative and migratory states required for vascular sprouting. If male and female endothelial cells regulate OCT4 differently, then the same VEGF stimulus could yield quantitatively different angiogenic outputs in men and women — with consequences for coronary collateral growth after a heart attack, tumor vascularization, pathological retinal neovascularization, and the performance of engineered vascular grafts. That possibility, the authors argue, is precisely why experimental ambiguity has become an unacceptable liability.

The biological premise is not speculative. A 2023 review by J. Robert in Atherosclerosis consolidated evidence that vascular endothelial cells from males and females differ measurably in proliferation, migration, barrier function, inflammatory signaling, and thrombotic behavior. Transcriptomic work by Rudnicki and colleagues, published in iScience in 2022, showed that adipose tissue endothelial cells exposed to obesogenic conditions carry sharply divergent sex-specific molecular signatures, implying that even metabolic stress is interpreted differently by male and female vasculature. Clinically, the fingerprints are familiar: ischemic heart disease presents differently in women, outcomes after peripheral revascularization diverge, and wound-healing kinetics differ by sex. In ophthalmology, Castellana and Chiappetta reported in Therapeutic Advances in Ophthalmology in 2025 that adverse reactions to anti-VEGF therapies used to suppress pathological retinal angiogenesis show sex-specific patterns. Regulators have taken note as well: since 2016, the U.S. National Institutes of Health has required applicants to treat sex as a biological variable in study design, a policy translated for bench scientists in a 2022 primer by Denfeld, Lee, and Habecker in the American Journal of Physiology-Heart and Circulatory Physiology.

Yet the letter’s sharpest criticism targets how that policy is being implemented at the laboratory bench. In the overwhelming majority of studies, investigators simply compare intact males with intact females. Such comparisons confound two variables that are mechanistically independent: the chromosome complement — XX in typical females, XY in typical males — and the hormonal milieu, including cyclic estradiol and progesterone exposure in females and comparatively tonic androgen exposure in males. When a study reports that female endothelial cells sprout faster, or that male cells express more OCT4 under VEGF stimulation, neither mechanistic interpretation is secure, because chromosomes and hormones changed simultaneously. The letter calls for designs that decouple the two. In animal work, that means models such as the four-core genotype, in which the Sry sex-determining gene is experimentally relocated so that XX mice can develop testes and XY mice can develop ovaries, yielding all four chromosome-gonad combinations and allowing chromosome effects to be read independently of gonadal secretions. In cell culture, it means comparing XX-derived and XY-derived endothelial lines under hormone-depleted conditions and then adding back physiologically calibrated doses of estradiol or androgens in controlled pulses rather than as uncharacterized background noise.

The distinction is not academic hair-splitting; it changes what a result can mean therapeutically. A purely hormonal effect on OCT4-driven angiogenesis would, in principle, be transient, dose-dependent, and pharmacologically negotiable — modifiable by adjusting hormone exposure, the timing of administration, or drug scheduling around hormonal cycles. A chromosomal effect, by contrast, would be cell-intrinsic, potentially stabilized epigenetically through X- or Y-linked dosage genes, and far harder to modulate except by targeting downstream effectors such as OCT4 itself or its angiogenic target genes. The authors also press for stricter control of variables that interact with both sex-linked mechanisms: donor age; vascular bed origin, since macrovascular and microvascular endothelial cells behave differently; culture passage number; cyclic versus tonic hormone exposure; and the differentiation state of the cells under study. Resolving OCT4’s contribution, they argue, requires layered measurement — quantitative PCR or immunoblotting for OCT4 abundance, chromatin immunoprecipitation to establish where OCT4 binds within angiogenic gene regulatory regions, and transcriptomic profiling of XX and XY cells held under matched hormonal conditions so that the chromosomal signal can finally be isolated and quantified.

The second pillar of the letter concerns measurement itself. Angiogenesis is quantified through a patchwork of assays that vary dramatically between laboratories: tube formation on Matrigel, spheroid-based sprouting, scratch-wound migration, aortic-ring outgrowth, and in vivo readouts such as laser-Doppler perfusion recovery after hindlimb ischemia, laser-induced choroidal neovascularization area, and tumor microvessel density marked by CD31 staining. Time points, normalization schemes, oxygen conditions, and statistical handling differ from one paper to the next, which makes effect sizes incomparable and meta-analyses unreliable. When a sex-specific effect is layered onto that noise, the authors warn, it becomes nearly impossible to determine whether OCT4-linked divergence between male and female endothelial cells is robust or an artifact of local protocol. Their remedy is a standardized, sex-stratified endpoint framework: pre-specified primary endpoints, parallel assessment of both sexes with adequate statistical power, mandatory sex-disaggregated reporting rather than pooled averages, and shared benchmarks that would allow an OCT4 effect measured in one laboratory to be compared directly with one measured in another. Without that common language, they argue, individual discoveries cannot accumulate into a coherent translational evidence base.

The translational stakes are concrete. Anti-VEGF agents such as ranibizumab, aflibercept, and off-label bevacizumab are mainstays for neovascular age-related macular degeneration and diabetic retinal disease, and the documented sex differences in their adverse-reaction profiles suggest that vascular responsiveness to angiogenesis blockade is not sex-neutral. If OCT4 status modulates how endothelial cells interpret VEGF signaling, then OCT4 expression levels or OCT4-regulated gene signatures could serve as sex-stratified biomarkers predicting which patients respond to anti-angiogenic therapy, who develops resistance, and who tolerates treatment poorly. In oncology, where tumor growth depends on recruiting new vasculature and anti-angiogenic drugs have shown sex-differentiated signals of efficacy and toxicity, an OCT4-informed framework could refine both trial enrollment and dosing. In ischemic cardiovascular medicine, therapeutic angiogenesis trials have historically struggled to meet their endpoints, and the letter suggests one underexamined reason: pooling the sexes may have averaged away real, opposing vascular responses, diluting effects that might have been detectable — and clinically actionable — in properly powered sex-stratified analyses.

The authors declare no competing interests, and the Letter is explicitly framed as a roadmap rather than a critique for its own sake — an effort to make a striking discovery implementation-ready. Its publication coincides with a decade-long institutional push, led by NIH policy and echoed by major journals, to treat sex as a fundamental biological variable rather than a demographic footnote. What Vijayasimha, Srikanth, and Jha add is specificity: for endothelial OCT4 biology to matter clinically, sex chromosomes and sex hormones must be separated experimentally, translational endpoints must be standardized across laboratories, and sex-disaggregated data must become the default product of angiogenesis research rather than an afterthought buried in supplementary tables. Whether the field adopts that discipline, the authors conclude, will determine whether OCT4 becomes the entry point for precision vascular medicine in men and women — or one more sex-specific signal that faded from view because no one built the machinery needed to test it properly.